- Home
- BLRX vs EVAX Comparison
BLRX vs EVAX Comparison
Compare BLRX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- EVAX
- Stock Information
- Founded
- BLRX 2003
- EVAX 2008
- Country
- BLRX Israel
- EVAX Denmark
- Employees
- BLRX N/A
- EVAX N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLRX Health Care
- EVAX Health Care
- Exchange
- BLRX Nasdaq
- EVAX Nasdaq
- Market Cap
- BLRX 17.1M
- EVAX 17.8M
- IPO Year
- BLRX 2011
- EVAX 2021
- Fundamental
- Price
- BLRX $3.50
- EVAX $5.75
- Analyst Decision
- BLRX Strong Buy
- EVAX Strong Buy
- Analyst Count
- BLRX 2
- EVAX 2
- Target Price
- BLRX $19.00
- EVAX $13.50
- AVG Volume (30 Days)
- BLRX 29.2K
- EVAX 855.7K
- Earning Date
- BLRX 11-24-2025
- EVAX 11-07-2025
- Dividend Yield
- BLRX N/A
- EVAX N/A
- EPS Growth
- BLRX N/A
- EVAX N/A
- EPS
- BLRX N/A
- EVAX N/A
- Revenue
- BLRX $17,251,000.00
- EVAX $3,176,000.00
- Revenue This Year
- BLRX N/A
- EVAX $129.34
- Revenue Next Year
- BLRX N/A
- EVAX N/A
- P/E Ratio
- BLRX N/A
- EVAX N/A
- Revenue Growth
- BLRX 1.19
- EVAX 1042.45
- 52 Week Low
- BLRX $2.30
- EVAX $1.20
- 52 Week High
- BLRX $22.60
- EVAX $15.50
- Technical
- Relative Strength Index (RSI)
- BLRX 37.77
- EVAX 49.57
- Support Level
- BLRX $3.51
- EVAX $5.29
- Resistance Level
- BLRX $3.89
- EVAX $6.82
- Average True Range (ATR)
- BLRX 0.24
- EVAX 1.29
- MACD
- BLRX -0.04
- EVAX -0.28
- Stochastic Oscillator
- BLRX 0.00
- EVAX 6.71
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.